Ocular Therapeutix To Present at Two Ophthalmology Meetings, May 4-9, 2024

2024 OIS Retina and ARVO meetings are being held in Seattle, Washington

BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at the Ophthalmology Innovation Source (OIS) Retina 2024 (May 4th) and the Association for Research in Vision and Ophthalmology (ARVO) 2024 meetings (May 5-9th) being held in Seattle, Washington.

Presentations at OIS Retina 2024:

• Session Title: “Spotlight on Drug Delivery”
  Session Date/Time: Saturday, May 4th, 11:15 AM – 12:00 PM PDT
  Ocular Presentation: 11:34 – 11:41 AM PDT
  Presenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer

• Panel Title: “The View from the Street”
  Session Date/Time: Saturday, May 4th at 5:00 – 5:30 PM PDT
  Moderator: Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer

Presentations at ARVO 2024:

• Oral Presentation: Pharmacodynamic efficacy of second-generation intravitreal axitinib implant (AXPAXLI) in a VEGF challenge rabbit model
  Session Date/Time: Thursday, May 9th 3:30 – 3:45 PM PDT
  Location: Yakima 1 - Seattle Convention Center - Arch Building
  Presenter: Chuck Blizzard, Vice President, Research & Development

• Poster Title: Long-term safety of repeated intravitreal axitinib implant (AXPAXLI) administrations in non-human primates
  Poster Board #: B0299
  Session Date/Time: Monday, May 6th 8:30 – 10:15 AM PDT
  Location: Exhibit Hall – Seattle Convention Center
  Presenter: Chintan Patel, PhD, Associate Director, Nonclinical Development

• Poster Title: Optimized pharmacokinetic profile of intravitreal axitinib implant (AXPAXLI):
  a comparison of first- and second-generation implants
  Poster Board #: B0300
  Session Date/Time: Monday, May 6th 8:30 – 10:15 AM PDT
  Location: Exhibit Hall – Seattle Convention Center
  Presenter: Madhoosudan Patil, PhD, Senior Scientist

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other diseases and conditions of the eye. AXPAXLI (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in the first of two planned pivotal Phase 3 trials for wet AMD, the SOL-1 trial, and a Phase 1 clinical trial for the treatment of NPDR. The clinical portfolio also includes PAXTRAVA (travoprost intracameral implant, also known as OTX-TIC), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension.